Board of Directors
Craig R. Smith, M.D.
Chairman of the Board of Directors, and Chief Executive Officer, member of the Science Committee and member of the New Hire Option Committee.
Dr. Smith joined the Company as a Director at the Companys inception in July 1993. Dr. Smith was elected President and Chief Executive Officer in August 1993 and was elected Chairman of the Board in January 1994. Prior to joining the Company, Dr. Smith was Senior Vice President for Business and Market Development at Centocor, Inc., a biotechnology corporation. Before joining Centocor, Dr. Smith served on the Faculty of the Department of Medicine at Johns Hopkins Medical School. Dr. Smith received his M.D. from the State University of New York at Buffalo in 1972 and received training in Internal Medicine at Johns Hopkins Hospital from 1972 to 1975. Dr. Smith serves on the Boards of the Maryland Chapter of the Cystic Fibrosis Foundation, the Greater Baltimore Committee, and the Greater Baltimore High Tech Council. Dr. Smith also serves as Chair for the Advisory Council for the Institute of Basic Biomedical Sciences at Johns Hopkins University.
George L. Bunting, Jr.
Director and Chairman of the Compensation Committee and member of the Audit Committee.
Mr. Bunting has been a Guilford director since May 1996. Mr. Bunting is president and chief executive officer of Bunting Management Group, a position he has held since July 1991. He formerly served as chairman of the board and chief executive officer of the Noxell Corporation (a Procter and Gamble Company as of November 1989). Mr. Bunting joined Noxell Corporation in 1966 as a product manager. In 1968, he was elected to the board of directors of Noxell. In March 1970, he was elected to the position of executive vice president and served as president and chief executive officer from November 1973 until April 1986, when he became chairman and chief executive officer. Mr. Bunting is a director of Mercantile Bankshares Corporation, Baltimore Equitable Insurance Company and Mercantile Safe Deposit and Trust Company. He served as Chairman of the Board of Trustees of the Johns Hopkins Health System, and Johns Hopkins Hospital from 1994 until 1998 and for Johns Hopkins Medicine from 1996 until 1998. Mr. Bunting continues to serve as a trustee for these institutions as well as Johns Hopkins University.
Joseph R. Chinnici
Director and member of the Audit Committee.
Mr. Chinnici joined the Board of Directors for Guilford in 2002. He currently serves as Senior Vice President, Finance and Chief Financial Officer at CIENA Corporation, a leading provider of intelligent optical networking systems and software, located in Linthicum, Maryland. Before being promoted to this position, he served as Vice President, Finance and Chief Financial Officer from May 1995 to August 1997, and Controller from September 1994 to May 1995. Previously, Mr. Chinnici acted as a financial consultant for Halston Borghese Inc., and held a variety of finance and accounting assignments with Playtex Apparel. Mr. Chinnici holds a B.S. degree in accounting from Villanova University and an M.B.A. from Southern Illinois University. Mr. Chinnici also currently serves on the board of directors for TR Systems.
Barry M. Fox
Director and member of the Compensation Committee.
Mr. Fox is a partner at the law firm of Cleary, Gottlieb, Steen & Hamilton, an international law firm based in New York City. Mr. Fox joined Guilford's Board in September 2002. Mr. Fox joined Cleary, Gottlieb in 1974 and became a partner in 1981. Mr. Fox received a J.D. degree, cum laude, in 1969 from Harvard Law School, where he was editor of the Harvard Law Review from 1967 to 1969. He received an undergraduate degree from Johns Hopkins University in 1965.
Elizabeth M. Greetham
Director and member of the Compensation Committee.
Ms. Greetham has been a Guilford director since November 1995. From 1992 to 1999, Ms. Greetham was portfolio manager of WPG Life Sciences Fund, L.P. and WPG Institutional Life Sciences Fund, L.P., and since 1990 she had been involved in health care investments for institutional, growth and individual high net worth accounts at Weiss, Peck & Greer, L.L.C. From June 1999 until August 2000, Ms. Greetham was Chief Financial Officer of Drug Abuse Sciences, Inc. In August 2000, Ms. Greetham was named Chief Executive Officer of Drug Abuse Sciences, Inc. She is a member of the Board of Directors of Drug Abuse Sciences, Inc.
Director and member of the Audit Committee and Science Committee.
Mr. Klein has been a Guilford director since August 1998. Mr. Klein is currently Managing Member of Gauss Capital Advisors, LLC, a consulting and investment advisory firm focused on medical technology, and a Venture Partner of MPM Capital, one of the largest venture capital firms devoted exclusively to the life sciences. Mr. Klein has over 15 years of experience as a health care portfolio manager and securities analyst at The Kaufmann Fund and T. Rowe Price Associates, Inc., including conceiving, launching and successfully managing the T. Rowe Price Health Sciences Fund for its first two years. From June, 1999, to September, 2000, Mr. Klein served as Vice President, Strategy for Medical Manager Corporation where he assisted senior executives until the company merged with WebMD Corporation. Mr. Klein earned an MBA from the Stanford Graduate School of Business, and a B.A. in economics, summa cum laude, from Yale University, where he was elected to Phi Beta Kappa. Mr. Klein is also a Director of NPS Pharmaceuticals, Inc.
Director, Chairman of the Audit Committee and Chairman of the Nominating Committee.
Mr. Nordmann became a Guilford Director in May 2000. Mr. Nordmann is currently Co-President of Global Health Associates, LLC (a consulting firm to life sciences companies). From 1994 until January 2000, Mr. Nordmann was a partner at Deerfield Management, a health care investment management firm where he served as an analyst and portfolio manager of a $1.2 billion health care sector fund. Prior to joining Deerfield Management, Mr. Nordmann was the Managing Director and Senior Health Care Analyst at PaineWebber Incorporated (a broker dealer) for approximately nine years. Mr. Nordmann has over 25 years experience in investment management specializing in the pharmaceutical industry. He received his B.A. in Business and Industrial Management from The Johns Hopkins University in 1963 and his MBA in Finance and Marketing from Fairleigh Dickinson University in 1966. Mr. Nordmann serves on the Boards of Directors of Shire Pharmaceuticals Group plc, Pharmaceutical Resources, Inc. and is a Trustee of The Johns Hopkins University.
Solomon H. Snyder, M.D.
Director, Chairman of the Science Committee, member of Nominating Committee and consultant to Guilford.
Dr. Snyder has been a Guilford director since Guilford's inception in July 1993 and a consultant of ours since August 1993. Dr. Snyder received his M.D. in 1962 from Georgetown Medical School, trained as a research associate with Julius Axelrod at the National Institute of Mental Health and completed his Psychiatry Residency at Johns Hopkins Hospital. He is presently director of the Department of Neuroscience at Johns Hopkins Medical School and Distinguished Service Professor of Neuroscience, Pharmacology and Molecular Sciences, and Psychiatry. Dr. Snyder has received a number of awards including the Albert Lasker Award in Basic Biomedical Research, the Wolf Prize and the Bower Award. He is a member of the U.S. National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Snyder is a director of Scios.
W. Leigh Thompson, M.D., Ph.D.
Director and member of the Compensation Committee and Science Committee.
Dr. Thompson has been a Guilford director since April 1995. Dr. Thompson joined Eli Lilly in 1982 and was appointed executive vice president for research in 1991 and chief scientific officer in 1993. Dr. Thompson retired from Eli Lilly in December 1994 and is currently an independent consultant (advising clients in the pharmaceutical industry). Dr. Thompson was a Professor of Medicine at Case Western Reserve University and President of the Society of Critical Care Medicine. Dr. Thompson is a Director of DepoMed, Inc., Inspire Pharmaceuticals, Inc., La Jolla Pharmaceutical Co., Medarex, Inc., Orphan Medical, Inc., Bioanalytical Systems, Inc., Conjuchem, Inc., Diabetogen and Sontra.
David C. U’Prichard, Ph.D.
Director and member of the Science Committee.
Dr. U’Prichard joined the Board of Directors in December 2003. He is currently President of Druid Consulting LLC, a specialized pharmaceutical and biotechnology-consulting firm, which provides customized services to life sciences clients in the United States and Europe. Dr. U’Prichard is also a Venture Partner and member of the health care team of Apax Partners Ltd., a global private equity provider. Previously, he was Chief Executive Officer of 3-Dimensional Pharmaceuticals (3DP) from 1999 to 2003. In addition, Dr. U’Prichard has held a variety of positions within the pharmaceutical and biotechnology industries, including, acting as President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals; Executive Vice President and International Research Director, and a Member of the Board of Zeneca Pharmaceuticals; General Manager Research Department, ICI Pharmaceuticals, and Vice President Biomedical Research, ICI Pharmaceuticals, and Senior Vice President and Scientific Director for Nova Pharmaceutical Corporation. He is currently a member of the board of directors of the Life Sciences Research Foundation in Baltimore, Maryland, and is a member of the board of directors of Lynx Therapeutics, ExSAR Corporation and Predict, Inc. Dr. U’Prichard is also Chairman of the board of directors for the Pennsylvania Biotechnology Association. From 1992 to 1997 Dr. U’Prichard was a member of the board of the Biotechnology Industry Organization (BIO), an international association of more than 1,000 biotechnology companies, academic institutions, biotechnology research centers and related organizations representing 33 nations.
This page was last updated on
Copyright© 2002 Guilford Pharmaceuticals Inc.